Prenatal Care Visit Schedule Reference: Standard Uncomplicated Pregnancy Timeline

Frequently Asked Questions

• Q Why does the WHO 2016 ANC model have 8 visits while ACOG recommends 14 visits for low-risk pregnancies?
  The difference between the WHO 2016 8-visit antenatal care model and the ACOG 14-visit standard schedule reflects separate guideline-development processes: WHO's 2016 ANC Recommendations were developed as a global population-health framework targeting reduction of preventable perinatal mortality across resource settings, with evidence review prioritizing essential contact milestones. The ACOG Practice Bulletin schedule reflects conventional U.S. outpatient prenatal visit frequency (monthly through 28 weeks, bi-weekly 28–36 weeks, weekly 36–41 weeks) accumulated over decades in U.S. obstetric practice. Both models are population-level frameworks. The choice of model, visit count, and any deviation is determined by the treating clinician and health system.
• Q How does prenatal visit scheduling differ between high-risk and low-risk pregnancies?
  High-risk pregnancies require additional visits per clinician plan. Population-level guideline schedules (WHO 8-visit and ACOG 14-visit) are written for uncomplicated low-risk pregnancies only. Pregnancies complicated by maternal pre-existing conditions (e.g., chronic hypertension, diabetes mellitus, autoimmune disease, prior adverse pregnancy outcome, multifetal gestation, or conditions diagnosed during pregnancy such as gestational hypertension, preeclampsia, gestational diabetes, fetal growth restriction, or preterm labor risk) are classified as higher-risk and are typically assigned additional contact points, specialist co-management, or increased surveillance frequency at the discretion of the responsible prenatal care clinician and health-system protocols. This page does not list high-risk schedule variants.
• Q Why is the gestational diabetes mellitus (GDM) screening window standardly 24 through 28 weeks?
  The 24–28 week window for GDM screening (one-step 75 g OGTT or two-step 50 g glucose challenge → 100 g OGTT) corresponds in population physiology to the gestational age at which placental diabetogenic hormone concentrations and maternal insulin resistance rise above the first-trimester baseline with sufficient magnitude to unmask glucose intolerance, while remaining early enough in the pregnancy that treatment (medical nutrition therapy and pharmacotherapy where indicated) has a demonstrated evidence base for reducing adverse perinatal outcomes including macrosomia, birth trauma, and neonatal hypoglycemia. Population-level guideline references (WHO 2013, ACOG PB 190 reaffirmed, SOGC) uniformly specify the 24–28 week window as the standard screening epoch in the absence of earlier risk indicators. Early screening may be indicated at clinician discretion in the presence of risk factors; such decisions are clinical, not addressed on this page.
• Q What is the rationale for the 35-week-0-day through 37-week-0-day Group B Streptococcus (GBS) rectovaginal swab window?
  The 35w0d–37w0d GBS rectovaginal swab collection window is specified in CDC MMWR 2010 (reaffirmed by subsequent CDC and ACOG guidance) on the basis of two population-level observations: (1) rectovaginal GBS colonization status within the 5 weeks immediately preceding delivery has been documented in surveillance studies to have the highest positive predictive value for intrapartum colonization compared with earlier sampling; and (2) selecting the 35–37 week window allows sufficient time for laboratory result availability and intrapartum antibiotic prophylaxis planning, while minimizing false-negative anamnestic shifts in colonization status that occur when sampling is performed substantially earlier. Swabs collected prior to 35w0d are not considered valid for intrapartum prophylaxis decisions in the absence of other clinical indicators.